Big pharma often plays “fund, license, kill” - a strategy which requires extreme precision in an industry where missing a competitor or hallucinating a patent number is a never-event.
Andrey Doronichev, CEO, OPTIC | Onyx Live | JPM 2026
Agentic AI makes a big splash in biopharma.
Related
Brad Sitko, CIO, XOMA Royalty | Onyx Live | JPM 2026
The biotech industry destroys billions in shareholder value every year - failed trials, depleted cash, and abandoned pipelines leaving investors with nothing.
Avi Veidman, CEO, Nucleai | Onyx Live | JPM 2026
90% of oncology drugs fail in clinical trials - costing billions and, more importantly, delaying life-saving treatments for patients who need them now.
Will biotech still be relevant in 2030? | Treehill Partners Ep. 3 | JPM 2026
Will large pharma's AI adoption and deployment to drug development redefine biotech's role and business model?
Paul Denslow, CEO, Intus Bio | Onyx Live | JPM 2026
38 trillion bacteria live in your gut — yet most microbiome tests can only identify them at the genus level, missing the strains that actually matter.